Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KTTA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $17.59M
- EPS (TTM)
- -$1.38
- Dividend yield
- None
- 52-week range
- 0.32 – 2.06
- Day range
- 0.4701 – 0.515
- Volume / Avg
- 100.72K / 705.64K
- Beta
- —
- Shares outstanding
- 36.75M
52-week range
KTTA stock today
Pasithea Therapeutics (KTTA) closed at $0.4787 on Nov 20, down 0.48% (-$0.0023), versus the S&P 500's 3.70% decline. Trading was light, with 100.72K shares changing hands, about 14% of the average daily volume. At this level, KTTA sits near the bottom of its 52-week range of $0.32 to $2.06: 76.8% below the high, set on Nov 28, 2025 and 49.6% above the low.
KTTA is down 62.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 63.9%. Pasithea Therapeutics has posted a net loss over the last twelve months (EPS of -$1.38), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pasithea Therapeutics
Company profilePasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Tiago Reis Marques M.D., Ph.D.
- Headquarters
- Miami Beach, FL
- Employees
- 5
- IPO year
- 2021
- Website
- pasithea.com
Financial highlights
Full financialsPasithea Therapeutics reported a net loss of $20.4 million, compared with a loss of $13.9 million a year earlier. Diluted earnings per share came in at -$2.91.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $486.56K | $15.06K |
| Growth | — | — | — | +3130.37% | — |
| Net income | $-20.43M | $-13.90M | $-15.96M | $-13.94M | $-2.17M |
| EPS (diluted) | $-2.91 | $-12.69 | $-0.42 | $-1.76 | $-0.21 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$3.00+526.70%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.20 vs $-0.21
- Surprise
- +4.76%
KTTA news
All KTTA news- Pasithea Therapeutics Corp. Reports Initial Phase 1/1b Data for PAS-004 and FDA Clearance of IND for Phase 2 TrialNasdaq
- Pasithea Reports Tumor Shrinkage With PAS-004 In Neurofibromatosis Trial; Stock UpNasdaqKTTA, BRK.B
- Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis ConferenceGlobeNewswire
- Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026GlobeNewswire
- Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026GlobeNewswire
Pasithea Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MRKRMarker Therapeutics Inc. | 1.09 | -17.42% | $18.17M | vs KTTA |
| COCPCocrystal Pharma Inc. | 0.95 | -2.05% | $18.30M | vs KTTA |
| AKTXAkari Therapeutics plc ADS | 7.18 | +7.00% | $16.70M | vs KTTA |
| SHPHShuttle Pharmaceuticals Holdings Inc. | 3.49 | -10.51% | $16.63M | vs KTTA |
| CPHIChina Pharma Holdings Inc. | 0.4384 | -13.00% | $18.86M | vs KTTA |
| LPCNLipocine Inc. | 1.48 | -1.33% | $16.39M | vs KTTA |
| ATOSAtossa Therapeutics Inc. | 1.60 | -8.86% | $15.92M | vs KTTA |
| PBMPsyence Biomedical Ltd. | 2.97 | +3.85% | $15.80M | vs KTTA |
Indexes, lists and sector
Pasithea Therapeutics stock FAQ
What is Pasithea Therapeutics's stock price today?
KTTA last traded at $0.4787 as of Nov 20, 4:00 PM EST, down 0.48% on the day. Prices are delayed at least 15 minutes.
Does Pasithea Therapeutics pay a dividend?
No. Pasithea Therapeutics does not currently pay a regular cash dividend.
Who is Pasithea Therapeutics's CEO?
Dr. Tiago Reis Marques M.D., Ph.D. is the chief executive officer of Pasithea Therapeutics Corp., which has about 5 employees.
Has KTTA ever split its stock?
Yes. The most recent KTTA stock split was a 1-for-20 split on Jan 2, 2024.
What is the KTTA 52-week high?
The 52-week high for KTTA is $2.06 and the 52-week low is $0.32. The stock is currently 76.8% below its high.